Placement | APEIRON Expands Executive Board and Appoints Dr. Anderson Gaweco as Chief Medical and Scientific Officer (CMSO)

APEIRON Biologics AG, the commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel cancer immunotherapies, has appointed Dr. Anderson Gaweco as Chief Medical and Scientific Officer, following a successful executive search conducted by The RSA Group.

Dr. Gaweco joins APEIRON from Innovimmune Biotherapeutics, New York, as founder & CEO/CSO, where he led the discovery of novel immuno-oncology and autoimmune therapeutic programs. Previously, he was CMO at Lifecycle Pharma in Denmark/USA, held Global Clinical Leader positions at Roche and Pfizer, and was Senior Medical Scientist at AstraZeneca. Before joining the industry, Dr. Gaweco held dual faculty appointments as Assistant Professor of Medicine & Pathology at Loyola University Medical Center in Chicago. He worked on several NMEs leading to successful multi-billion dollar marketed pharmaceutical products: Xeljanz®, Cellcept®, Zenapax®, Prograf®, Pegasys®, Copegus®, Nexium® & Crestor®. Dr. Gaweco received his M.D., Ph.D. in Immunology magna cum laude and obtained his residency in Pathology at the Ruprecht-Karls-Universität Heidelberg, Germany. He has completed clinical clerkships at Harvard, Oxford and the Mayo Clinic, and executive management trainings at the London Business School and Harvard School of Public Health. Dr. Gaweco is author or co-author of over 100 peer-reviewed journal articles, book chapters, abstracts and several worldwide patents of NME immunotherapies in immuno-oncology and autoimmunity. He is currently Adjunct Professor at Georgetown University School of Medicine.

Commenting on the appointment, Nicola Harding, Partner with The RSA Group, said:  “It was a pleasure and a privilege to work with the APEIRON Board on this search project. Dr. Gaweco will bring a wealth of cutting-edge scientific experience and creativity to this highly innovative and forward-thinking company, which is a recognised leader in the burgeoning immuno-oncology space”.

Read the full press release here:  https://www.apeiron-biologics.com/images/news/20180828_APEIRON_NewCMSO_ENG.pdf